Meeting Banner
Abstract #1009

Microstructural Diffusion-Weighted (VERDICT) MRI Metrics are Repeatable and Show Potential at Characterising Gleason 7 Prostate Cancer Non-Invasively

Edward William Johnston1, Elisenda Bonet-Carne2, Hayley Pye3, Joey Clemente1, Ben Yvernault2, Dominic Patel4, Susan Heavey3, Mrishta B Appayya1, Alexandra Saborowska5, Ashwin Sridhar6, Greg Shaw6, Sebastien Ourselin2, David Hawkes2, Caroline Moore6, Hayley Whitaker3, Manuel Rodriguez-Justo4, Alexander Freeman4, Eleftheria Panagiotaki2, Daniel Alexander2, and Shonit Punwani1

1Centre for Medical Imaging, University College London, London, United Kingdom, 2Centre for Medical Image Computing, University College London, London, United Kingdom, 3Research Department for Tissue & Energy, University College London, London, United Kingdom, 4Department of Pathology, University College London Hospital, University Street, United Kingdom, 5Radiology, University College London Hospitals, London, United Kingdom, 6Department of Urology, University College London Hospital, London, United Kingdom

In this study we we assess the repeatability of VERDICT (Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumours) MRI parameters in prostate cancer consider their ability to distinguish between Gleason grades compared with the standard ADC model in 71 patients. Four of the parametric maps derived from the VERDICT technique were found to be satisfactorily repeatable for use as a clinical tool, and are capable of identifying a Gleason 7 component in prostate cancer where ADC failed to do so. VERDICT therefore holds great potential for use in clinical prostate cancer management pathways in the future.

This abstract and the presentation materials are available to members only; a login is required.

Join Here